One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
U.S. Newswire, May, 2009
To: MEDICAL EDITORS
Contact: Jessica Otitigbe of Rensselaer Polytechnic Institute, 1- 518-276-6050, otitij@rpi.edu
TROY, N.Y., May 8 /PRNewswire-USNewswire/ -- For more than 10 years, Mark Wentland, professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, led a Rensselaer team in the discovery of a family of novel opioid receptor compounds with the potential to treat nervous system disorders and addiction. The family of compounds was licensed to Alkermes Inc., and the company identified a lead product candidate from the library. Clinical trials with the candidate, known as ALKS 33, began in December 2008.
Wentland said the "eureka moment" occurred with the realization that an opioid drug that his group discovered had triggered...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- LIFO vs. FIFO: a return to the basics
